A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Enith1
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
2 other identifiers
interventional
2,000
19 countries
164
Brief Summary
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Mar 2026
164 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 16, 2026
CompletedFirst Posted
Study publicly available on registry
January 20, 2026
CompletedStudy Start
First participant enrolled
March 16, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 24, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 28, 2028
July 20, 2026
July 1, 2026
2.4 years
January 16, 2026
July 17, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percent (%) Change from Baseline in Body Weight at Week 72
Baseline through Week 72
Secondary Outcomes (43)
Percentage of Participants Achieving ≥5% Body Weight Loss from Baseline at Week 72
Baseline and Week 72
Percentage of Participants Achieving ≥10% Body Weight Loss from Baseline at Week 72
Baseline and Week 72
Percentage of Participants Achieving ≥15% Body Weight Loss from Baseline at Week 72
Baseline and Week 72
Percentage of Participants Achieving ≥20% Body Weight Loss from Baseline at Week 72
Baseline and Week 72
Percentage of Participants Achieving ≥25% Body Weight Loss from Baseline at Week 72
Baseline and Week 72
- +38 more secondary outcomes
Study Arms (4)
Arm 1: Placebo
PLACEBO COMPARATORArm 2: Enicepatide Dosing Regimen 1
EXPERIMENTALArm 3: Enicepatide Dosing Regimen 2
EXPERIMENTALArm 4: Enicepatide Dosing Regimen 3
EXPERIMENTALInterventions
Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.
Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.
Eligibility Criteria
You may qualify if:
- Participants must have at screening:
- Body mass index (BMI) greater than or equal to (≥)30.0 kg/m\^2; or
- BMI ≥27.0 kg/m\^2 and \<30.0 kg/m\^2 with at least one weight-related comorbidity, such as prediabetes, hypertension, dyslipidemia, diagnosis of obstructive sleep apnea, or weight-related cardiovascular disease
- History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight
- Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)
You may not qualify if:
- History of Type 1 diabetes mellitus (T1DM) or T2DM, or history of ketoacidosis or hyperosmolar state/coma. Prior, but not current, diagnosis of gestational diabetes is allowed if no history of diabetes is recorded since.
- Self-reported change in body weight \>5 kg within 3 months prior to screening
- Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)
- Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.
- Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)
- History of acute or chronic pancreatitis or clinically significant gallbladder disease. History of acute pancreatitis caused by gallstones or clinically significant gallbladder disease is allowed if the participant had a cholecystectomy to resolve the problem at least 3 months prior to screening.
- Poorly controlled hypertension at screening
- Any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure.
- Have a history of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, or other serious mood or anxiety disorder). Participants with MDD or generalized anxiety disorder whose disease state is considered stable within 1 year prior to screening and expected to remain stable throughout the course of the study, in the opinion of the investigator, are allowed provided that they are not receiving prohibited medication.
- Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptor triple agonist) within 6 months prior to randomization
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (164)
Pinnacle Research Group
Anniston, Alabama, 36207, United States
Alabama Clinical Therapeutics
Birmingham, Alabama, 35235, United States
University of Alabama at Birmingham
Birmingham, Alabama, 35294-3360, United States
Arizona Clinical Trials
Tucson, Arizona, 85711, United States
Artemis Institute for Clinical Research, LLC
San Diego, California, 92123, United States
Yale University
New Haven, Connecticut, 06519, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, 30291, United States
East-West Medical Research Institute
Honolulu, Hawaii, 96814, United States
Elevate Clinical Research
Gurnee, Illinois, 60031, United States
Knownwell
Schaumburg, Illinois, 60194, United States
Endeavor Health
Skokie, Illinois, 60077, United States
Monroe Biomedical Research
Louisville, Kentucky, 40213, United States
Ascension DePaul Health
New Orleans, Louisiana, 70127, United States
Knownwell
Needham, Massachusetts, 02492, United States
International Diabetes Center At Park Nicollet
Minneapolis, Minnesota, 55416, United States
DelRicht Research at Gulfport Memorial
Gulfport, Mississippi, 39503, United States
Clinvest Research LLC
Springfield, Missouri, 65807, United States
Rochester Clinical Research
Buffalo, New York, 14217, United States
Hometown Urgent Care and Research - Dayton
Dayton, Ohio, 45424, United States
Delricht Research of Tulsa Clinical Trials
Tulsa, Oklahoma, 74133, United States
Headlands Reseach- Summit
Portland, Oregon, 97210, United States
Suburban Research Associates - West Chester Office
West Chester, Pennsylvania, 19380, United States
Trial Management Associates
Myrtle Beach, South Carolina, 29572, United States
Circle Clinical Research
Sioux Falls, South Dakota, 57104, United States
Innovative Clinical Research
Clarksville, Tennessee, 37040, United States
Clinical Research Associates
Nashville, Tennessee, 37203, United States
Bellaire Clinical Research, LLC
Bellaire, Texas, 77401, United States
South Texas Research Institute - Brownsville
Brownsville, Texas, 78520, United States
South Texas Clinical Research
Corpus Christi, Texas, 78404, United States
University of Texas Southwestern Medical Center - Children's Medical Center Dallas
Dallas, Texas, 75390, United States
Elevate Clinical
Houston, Texas, 77058, United States
Houston Research Institute
Houston, Texas, 77079, United States
Elevate Clinical
McAllen, Texas, 78504, United States
Pinnacle Clinical Research - South San Antonio
San Antonio, Texas, 78222, United States
IMA Clinical Research - San Antonio
San Antonio, Texas, 78229, United States
Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance
Southlake, Texas, 76092, United States
CINME
Buenos Aires, C1056ABI, Argentina
CEDIC Centro de Investigaciones Clinicas
Buenos Aires, C1060ABN, Argentina
Centro Medico Viamonte SRL
Buenos Aires, C1120AAC, Argentina
IME - Instituto Médico Especializado
Buenos Aires, C1405BCH, Argentina
Instituto centenario
Ciudad Autonoma Buenos Aires, C1204AAD, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Ciudad Autonoma Buenos Aires, C1425AGC, Argentina
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, B7600FYK, Argentina
Paratus Clinical Western Sydney
Blacktown, New South Wales, 2148, Australia
Southern Adelaide Diabetes and Endocrine Services (SADES)
Oaklands Park, South Australia, 5046, Australia
Baker Heart and Diabetes Insitute
Melbourne, Victoria, 3004, Australia
AZORG Campus Aalst-Moorselbaan
Aalst, 9300, Belgium
Hospital Erasme
Brussels, 1070, Belgium
UZ Leuven Gasthuisberg
Leuven, 3000, Belgium
CHU de Liège (Sart Tilman)
Liège, 4000, Belgium
AZ Delta (Campus Rumbeke)
Roeselare, 8800, Belgium
CPQuali Pesquisa Clinica Ltda
São Paulo, São Paulo, 01228-000, Brazil
Centro de Pesquisas Clinicas
São Paulo, São Paulo, 01228-200, Brazil
C-health Partners Inc
Calgary, Alberta, T2V 4J2, Canada
Unity Healthcare Clinic
Surrey, British Columbia, V3T 4G8, Canada
Aggarwal and Associates
Brampton, Ontario, L6T 0G1, Canada
Hamilton Medical Research Group
Hamilton, Ontario, L8L 5G4, Canada
Wharton Medical Clinic
Hamilton, Ontario, L8L 5G8, Canada
Bluewater Clinical Research Group
Sarnia, Ontario, N7T 4X3, Canada
Diex Recherche Trois-Rivieres
Trois-Rivières, Quebec, G9A 4P3, Canada
Alpha Recherche Clinique
Québec, G2J0C4, Canada
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212002, China
Yan'an University Xianyang Hospital
Xianyang, Shaanxi, 712000, China
Jinan Central Hospital
Jinan, Shandong, 250013, China
Peking University People's Hospital
Beijing, 100044, China
Beijing Pinggu Hospital
Beijing, 101200, China
The First Hospital of Jilin University
Changchun, 130021, China
The Second People's Hospital of Hefei
Hefei, 230011, China
Huizhou Central People's Hospital
Huizhou, 516001, China
Hebei Petro China Central Hospital
Langfang, 065000, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, DUMMY_VALUE, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, 210003, China
Pingxiang People's Hospital
Pingxiang, 337000, China
Shanghai Pudong New Area People's Hospital
Shanghai, 201299, China
The First Affiliated Hospital of Soochow University
Suzhou, 215333, China
MUDr. Alena Váchová, Diabetologie
České Budějovice, 37011, Czechia
Edumed s.r.o.;Diabetologická ambulance
Náchod, 54701, Czechia
DIALINE s.r.o.
Plze?, 301 00, Czechia
MediSpo Clinic
Prague, 120 00, Czechia
DiaVize
Prague, 140 00, Czechia
MEDICON a.s. - Poliklinika Bud?jovická
Prague, 140 00, Czechia
CHU d'Angers
Angers, 49933, France
CHU de Rouen - HOPITAL Bois Guillaume
Bois-Guillaume, 76230, France
CHU Dijon - Hopital Francois Mitterrand
Dijon, DUMMY_VALUE, France
Hopital Européen Georges Pompidou;Service d?endocrinologie, diabétologie et nutrition
Paris, 75015, France
Groupe Hospitalier Pitié Salpétrière;Service d?endocrinologie, diabétologie et nutrition
Paris, 75671, France
CHU de Bordeaux;Service d?endocrinologie, diabétologie et nutrition
Pessac, 33604, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
CHU DE POITIERS - Hôpital de la Milétrie
Poitiers, 86021, France
CHU de Nantes - Hopital Laennec
Saint-Herblain, 44800, France
Hector-Center für Ernährung, Bewegung und Sport, Universitätsklinikum Erlangen;Medizinische Klinik 1 ? Gastroenterologie, Pneumologie und Endokrinologie
Erlangen, 91054, Germany
InnoDiab Forschung GmbH
Essen, 45136, Germany
Medizentrum Essen Borbeck
Essen, 45355, Germany
Unterfrintroper Hausarztzentrum
Essen, 45359, Germany
Diabeteszentrum Hamburg West
Hamburg, 22607, Germany
Mesut Durmaz - Facharzt für Innere Medizin, Endokrinologie & Diabetologie
Hof, 95030, Germany
Zentrum für klinische Forschung Köln - Dünnwald;Dünnwald Praxis
Köln - Dünnwald, 51069, Germany
Schwerpunktpraxis für Diabetes und Ernährungsmedizin, Dr. med. Winfried Keuthage
Münster, 48153, Germany
Diabetologische Schwerpunktpraxis Pirna Hausärztliche Versorgung
Pirna, 01796, Germany
DRC Gyogyszervizsgalo Kozpont Kft
Balatonfüred, 8230, Hungary
Semmelweis Egyetem, Varosmajori Sziv- es Ergyogyaszati Klinika
Budapest, 1122, Hungary
MED-TIMA Kft.
Budapest, 1132, Hungary
Anyagcsere Centrum Csepel/Szatmári-Med Kft.;Diabetology
Budapest, 1213, Hungary
Debreceni Egyetem, Klinikai Kozpont;Belgyogyaszati Klinika, A epulet
Debrecen, 4032, Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont;Belgyogyaszati Klinika
Szeged, 6725, Hungary
Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz;2nd Department of Internal Medicine, Nephrological and Diabetological Center
Székesfehérvár, 8000, Hungary
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Abruzzo, 24127, Italy
Azienda Ospedaliero-Universitaria "Renato Dulbecco" Catanzaro
Catanzaro, Calabria, 88100, Italy
A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
Bologna, Emilia-Romagna, 40138, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, 00168, Italy
I.R.C.C.S Policlinico San Donato
San Donato Milanese (MI), Lombardy, 20097, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Sicily, 90127, Italy
Università Degli Studi di Pisa - Ospedale di Cisanello Pisa
Pisa, Tuscany, 56124, Italy
Universita Degli Studi Di Perugia
Perugia, Umbria, 06129, Italy
Kasugai Municipal Hospital
Aichi, 486-8510, Japan
Fukuhama Chuo Clinic
Fukuoka, 810-0066, Japan
NTT Medical Center Sapporo
Hokkaido, 060-0061, Japan
Hasegawa Medicine Clinic
Hokkaido, 066-0032, Japan
The University of Osaka Hospital
Osaka, 565-0871, Japan
Higashijujo Sakai Diabetes Internal Medicine Clinic
Tokyo, 114-0001, Japan
Radboud Universitair Medisch Centrum
Nijmegen, 6525 GA, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
NZOZ Specialistyczny Osrodek Internistyczno - Diabetologiczny
Bialystok, 15-435, Poland
Centrum Medyczne Kermed Renata Bijata-Bronisz i Ewa Kowali?ska Sp.j.
Bydgoszcz, 85-231, Poland
Indywidualna Specjalistyczna Praktyka Lekarska Krzysztof Cymerman
Gdynia, 81-157, Poland
Centrum Medyczne ALL-MED
Krakow, 30-033, Poland
Gabinety Medyczne MATUSZEK
Lublin, 20-064, Poland
Centrum Medyczne Clinicly
Opole, 45-047, Poland
Osrodek Badan Klinicznych Metabolica
Tarnów, 33-100, Poland
Polsko-Amerykanskie Kliniki Serca;X Oddzial Kardiologii Inwazyjnej, Elektrofizjologii i Elektrostymulacji
Tychy, 43-100, Poland
ETG Warszawa
Warsaw, 02-677, Poland
ETG Zamosc
Zamo??, 22-400, Poland
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, 13620, South Korea
Konyang University Hospital
Daejeon, 35365, South Korea
Chosun University Hospital
Gwangju, 61453, South Korea
Gachon University Gil Medical Center
Incheon, 21565, South Korea
Seoul National University Hospital
Seoul, 03080, South Korea
Kangbuk Samsung Hospital
Seoul, 03181, South Korea
Asan Medical Center
Seoul, 05505, South Korea
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
Hospital San Rafael A Coruna
A Coruña, LA Coruna, 15006, Spain
Hospital del Mar
Barcelona, 08003, Spain
Hospital Universitario Vall d Hebron
Barcelona, 08035, Spain
Hospital Ruber Juan Bravo
Madrid, 28006, Spain
Hospital Clinico San Carlos
Madrid, 28040, Spain
Hospital Quironsalud Infanta Luisa
Seville, 41010, Spain
Hospital Vithas Sevilla
Seville, 41950, Spain
Hospital Universitari i Politècnic La Fe
Valencia, DUMMY_VALUE, Spain
Changhua Christian Hospital
Changhua, 50006, Taiwan
Chia-Yi Christian Hospital
Chiayi City, 600, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 80756, Taiwan
Chung Shan Medical University Hospital
Taichung, 40201, Taiwan
China Medical University Hospital
Taichung, 40447, Taiwan
National Cheng Kung University Hospital
Tainan, 70403, Taiwan
National Taiwan University Hospital
Taipei, 10048, Taiwan
Taipei Veterans General Hospital
Taipei, 112, Taiwan
Soham Staploe Medical Centre
Soham, Cambridgeshire, CB75JD, United Kingdom
Rowden Surgery
Chippenham, Wiltshire, SN15 2SB, United Kingdom
Monklands Hospital
Airdrie, ML6 0JS, United Kingdom
Queen Elizabeth University Hospital Glasgow
Glasgow, G51 4TF, United Kingdom
Leicester General Hospital
Leicester, LE5 4PW, United Kingdom
Hammersmith Hospital
London, W12 0HS, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP, United Kingdom
Singleton Hospital
Swansea, SA2 8QA, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Central Study Contacts
Reference Study ID Number: WC45725 https://forpatients.roche.com/ No attachments to email below.
CONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 16, 2026
First Posted
January 20, 2026
Study Start
March 16, 2026
Primary Completion (Estimated)
July 24, 2028
Study Completion (Estimated)
August 28, 2028
Last Updated
July 20, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing